Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF
Conclusions:
This study indicates that genetic and phenotypic variation of both TFPIα and TFPIβ, more than TF, are markers of cancer progression. Together with the previously demonstrated tumor suppressor effects of TFPI, the beneficial effect of tumor expressed TFPI on survival, renders TFPI as a potential anticancer agent, and the clinical significance of TFPI in cancer deserves further investigation.
Source: Breast Cancer Research - Category: Cancer & Oncology Authors: Mari TinholtHans VollanKristine SahlbergSandra JernströmFatemeh KavehOle LingjærdeRolf KåresenTorill SauerVessela KristensenAnne-Lise Børresen-DalePer SandsetNina Iversen Source Type: research
More News: Biology | Breast Cancer | Cancer | Cancer & Oncology | Genetics | Molecular Biology | Study | Thrombosis